Numab Therapeutics from Wädenswil in the canton of Zurich has concluded a development and licensing agreement with the Japanese company Ono Pharmaceutical Co. According to a press release, this relates to a multispecific antibody candidate “targeting a novel immuno-oncology target”. Toichi Takino of Ono comments: “We hope that the program candidate generated through our work with Numab will become a therapeutic option for patients with cancer who may benefit from this new treatment modality.” The two companies have been working together on this since 2017.
As part of the licensing agreement, Ono receives the intellectual property rights as well as the exclusive global development and marketing rights. In return for the research work and licensing, Numab will receive up to 258 million Swiss francs in research funds, upfront and milestone payments, and tiered single-digit to double-digit licensing fees for future sales.
CEO of Numab David Urech comments: “We are proud to have advanced this novel multispecific antibody candidate against a new and very challenging immuno-oncology target to this milestone. The licensing of the asset is an affirmation of our platform’s ability to create novel and unique pharmacology.”
Both companies hope to continue to use the “synergy between Numab’s multispecific antibody platform and Ono’s deep immuno-oncology expertise” for joint research into drugs to advance the immune-oncology pipeline.
Related news
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space